Refinement of screening for familial pancreatic cancer

Gut

Volumn 65, Issue 8, 2016, Pages 1314-1321

  Bartsch, D K ^a   Slater, E P ^a   Carrato, A ^b   Ibrahim, I S ^c   Guillen Ponce, C ^b   Vasen, H F A ^c   Matthai E ^a   Earl, J ^b   Jendryschek, F S ^a   Figiel, J ^a   Steinkamp, M ^a   Ramaswamy, A ^a   Vazquez Sequeiros E ^b   Munoz Beltran M ^b   Montans, J ^b   Mocci, E ^b   Bonsing, B A ^c   Wasser, M ^c   Kloppel G ^d   Langer, P ^a,e   Fendrich, V ^a   Gress, T M ^a   more..

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e Klinikum Hanau GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGE; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RISK; CANCER SCREENING; CDKN2A GENE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC VALUE; EARLY CANCER DIAGNOSIS; ENDOSCOPE; ENDOSCOPIC ULTRASONOGRAPHY; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENE MUTATION; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONSET AGE; PALB2 GENE; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PATIENT RISK; PATIENT SAFETY; PRIORITY JOURNAL; TERTIARY CARE CENTER; TUMOR SUPPRESSOR GENE; ULTRASOUND PROCESSOR; VERY ELDERLY; CANCER STAGING; CARCINOMA; DIAGNOSTIC IMAGING; GERMANY; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; TIME FACTOR;

AGE OF ONSET; CARCINOMA; EARLY DETECTION OF CANCER; ENDOSONOGRAPHY; FEMALE; GERMANY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; TIME FACTORS;

EID: 84973295095     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-311098     Document Type: Article

References (31)

1. Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007;56:1460-9.
2. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339-47.
3. Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-55.
4. Kimmey MB, Bronner MP, Byrd DR, et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002;56:S82-6.
5. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: An EUS-based approach. Clin Gastroenterol Hepatol 2004;2:606-21.
6. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: A prospective controlled study. Clin Gastroenterol Hepatol 2006;4:766-81.
7. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-Time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009;104:2175-81.
8. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009;58:1410-18.
9. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: A comprehensive strategy of imaging and genetics. Clin Cancer Res 2010;16:5028-37.
10. Canto MI, Hruban RH, Fishman EK, et al., American Cancer of the Pancreas Screening (CAPS) Consortium. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012;142:796-804; quiz e14-15. http://dx.doi.org/10.1053/j.gastro.2012.01.005
11. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011;106:946-54.
12. Al-Sukhni W, Borgida A, Rothenmund H, et al. Screening for pancreatic cancer in a high-risk cohort: An eight-year experience. J Gastrointes Surg 2012;16:771-83.
13. Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 2011;140:850-6.
14. Del Chiaro M, Verbeke CS, Kartalis N, et al. Short-Term results of a magnetic resonance imaging-based Swedish screening program for individuals at risk for pancreatic cancer. JAMA Surg 2015;150:512-18.
15. Harinck F, Konings IC, Kluijt I, et al. A multicenter comparative prospective blinded anlaysis of EUS and MRI for screening pancreatic cancer in high-risk individuals. Gut Published Online First: 18 May 2015. doi: 10.1136/gutjnl-2014-308008
16. Potjer TP, Schot I, Langer P, et al. Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res 2013;19:442-9.
17. Vasen H, Ibrahim I, Ponce CG, et al. The benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-Term prospective follow-up studies from three European expert centres. J Clin Oncol Published Online First: 25 Apr 2016. doi: pii:JCO640730
18. Bartsch DK, Kress R, Sina-Frey M, et al. Prevalence of familial pancreatic cancer in Germany. Int J Cancer 2004;110:902-6.
19. Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical mole melanoma associated with a specific 19 deletion of p16 ( p16-Leiden). Int J Cancer 2000;87:809-11.
20. Mocci E, Guillen-Ponce C, Earl J, et al. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Eur J Cancer 2015;51:1911-17.
21. Schneider R, Slater EP, Sina M, et al. German national case collection for familial pancreatic cancer (FaPaCa): Ten years experience. Fam Cancer 2011;10:323-30.
22. Lynch HT, Lanspa SJ, Fitzgibbons RJ Jr, et al. Familial pancreatic cancer ( part 1): genetic pathology review. Nebr Med J 1989;74:109-12.
23. Slater EP, Langer P, Fendrich V, et al. Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 2010;9:335-43.
24. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010;78:490-4.
25. Bartsch DK, Dietzel K, Bargello M, et al. Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer 2013;12:89-96.
26. Detlefsen S, Sipos B, Feyerabend B, et al. Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Arch 2005;447:800-5.
27. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-86.
28. Petersen GM, de Andrade M, Goggins M, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2006;15:704-10.
29. McFaul CD, Greenhalf W, Earl J, et al. Anticipation in familial pancreatic cancer. Gut 2006;55:252-8.
30. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-17.
31. Yu J, Blackford AL, Dal Molin M, et al. Time to progression of pancreatic ductal adenocarcinoma from low-To-high tumour stages. Gut 2015;64:1783-9.